[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337998-105":59,"doc-detail-337998-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","impact-of-different-age-ranges-on-the-benefits-and-harms-of-the-breast-cancer-screening-programme-by-the-eu-topia-tool","Impact of different age ranges on the benefits and harms of the breast cancer screening programme by the EU-TOPIA tool","","Study simulates long-term outcomes of breast cancer screening under different eligible age ranges for the Valencia Region (Spain). Using the EU-TOPIA tool and a biennial screening interval, three scenarios (S1: 45–69, S2: 50–69, S3: 45–74) were modeled across multiple participation rates. Outcomes included breast cancer mortality reduction and harms via false positives and overdiagnosis. All scenarios reduced breast cancer mortality, while increasing age ranges also increased false positives and overdiagnosis probability.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-different-age-ranges-on-the-benefits-and-harms-of-the-breast-cancer-screening-programme-by-the-eu-topia-tool/337998/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-different-age-ranges-on-the-benefits-and-harms-of-the-breast-cancer-screening-programme-by-the-eu-topia-tool/337998.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the study address about breast cancer screening?","Question",{"text":113,"@type":114},"It evaluates how different eligible age ranges affect the balance between benefits (breast cancer mortality reduction) and harms (false positives and overdiagnosis) in the Valencia Region screening programme.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were age range scenarios and participation rates modeled?",{"text":118,"@type":114},"Three scenarios (45–69, 50–69, and 45–74) were simulated with a biennial screening interval, across four participation rates based on current participation and increases of +5%, +10%, and +20%.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main benefits observed across scenarios?",{"text":122,"@type":114},"Breast cancer mortality decreased in all age-range scenarios, with larger reductions in scenarios including older eligible ages.",{"name":124,"@type":111,"acceptedAnswer":125},"What harms changed when expanding the eligible age range?",{"text":126,"@type":114},"As age range increased, the probability of false positives and overdiagnosis also increased, even though mortality reductions remained evident.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},337998,1790960121,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","European Journal of Public Health, Vol. 34, No. 4, 806–811  \n\\# The Author(s) 2024. Published by Oxford University Press on behalf of the European Public Health Association.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([https://creativecommons](https://creativecommons). org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](journals.permissions@oup.com)  \n[https://doi.org/10.1093/eurpub/ckae068](https://doi.org/10.1093/eurpub/ckae068) Advance Access published on 5 April 2024  \nImpact of different age ranges on the benefits and harms of the breast cancer screening programme by the EU-TOPIA tool  \nMarina Pinto-Carb1, Mercedes Vanaclocha-Esp 1, Javier Mart n-Pozuelo 1,  \nPaula Romeo-Cervera 1, Marta Hernndez-Garc a2, Josefa Ib~nez 1, 3, Susana Castn-Cameo 1,4, Dolores Salas 1, Nicolien T. van Ravesteyn5, Harry de Koning5, scar Zurriaga  6, 7, Ana Molina-Barcel1  \n1 Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain  \n2 Environmental Health Service, Utiel Public Health Centre, Ministry of Universal and Public Health, Utiel, Valencia Region, Spain  \n3 Healthcare Integration Service, Directorate General for Health Care, Regional Ministry of Health, Valencia, Spain  \n4 Screening Programs Service, General Directorate of Public Health, Regional Ministry of Health, Valencia, Spain  \n5 Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands  \n6 Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Legal Medicine, University of Valencia, Valencia, Spain  \n7 Joint Research Unit on Rare Diseases, FISABIO-University of Valencia (FISABIO-UVEG), Valencia, Spain  \nCorrespondence: Mercedes Vanaclocha-Esp Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Av. Catalunya, 21, 46020 Valencia, Spain, Tel: þ34 961926317, e-mail: mercedes.vanaclocha@fisabio.es  \nBackground: The recommendation for the implementation of mammography screening in women aged 45–49 and 70–74 is conditional with moderate certainty of the evidence. The aim of this study is to simulate the longterm outcomes (2020–50) of using different age range scenarios in the breast cancer screening programme of the Valencia Region (Spain), considering different programme participation rates. Methods: Three age range scenarios (S) were simulated with the EU-TOPIA tool, considering a biennial screening interval: S1, 45–69 years old (y); S2, 50–69 y and S3, 45–74 y. Simulations were performed for four participation rates: A ¼ current participation (72 .7%), B ¼ þ5%, C ¼ þ10% and D ¼ þ20% . Considered benefits: number (N􀀎 ) of in situ and invasive breast cancers (BC) (screen vs. clinically detected), N􀀎 of BC deaths and % BC mortality reduction. Considered harms: N􀀎 of false positives (FP) and % overdiagnosis. Results: The results showed that BC mortality decreased in all scenarios, being higher in S3A (32.2%) than S1A (30.6%) and S2A (27.9%) . Harms decreased in S2A vs. S1A (N􀀎 FP: 236 vs. 423, overdiagnosis: 4.9% vs. 5.0%) but also benefits (BC mortality reduction: 27.9% vs. 30.6%, N􀀎 screendetected invasive BC 15/28 vs. 18/25) . In S3A vs. S1A, an increase in benefits was observed (BC mortality reduction: 32.2% vs. 30.6%), N􀀎 screen-detected in situ B: 5/2 vs. 4/3), but also in harms (N􀀎 FP: 460 vs. 423, overdiagnosis: 5.8% vs. 5.0%) . Similar trends were observed with increased participation. Conclusions: As the age range increases, so does not only the reduction in BC mortality, but also the probability of FP and overdiagnosis.  \nIntroduction  \nIn 2020, there were 2 million new ca","cbCaimcTksrK9IHn","https://ap.wps.com/l/cbCaimcTksrK9IHn","pdf",957775,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What question does the study address about breast cancer screening?\",\"answer\":\"It evaluates how different eligible age ranges affect the balance between benefits (breast cancer mortality reduction) and harms (false positives and overdiagnosis) in the Valencia Region screening programme.\"},{\"question\":\"How were age range scenarios and participation rates modeled?\",\"answer\":\"Three scenarios (45–69, 50–69, and 45–74) were simulated with a biennial screening interval, across four participation rates based on current participation and increases of +5%, +10%, and +20%.\"},{\"question\":\"What were the main benefits observed across scenarios?\",\"answer\":\"Breast cancer mortality decreased in all age-range scenarios, with larger reductions in scenarios including older eligible ages.\"},{\"question\":\"What harms changed when expanding the eligible age range?\",\"answer\":\"As age range increased, the probability of false positives and overdiagnosis also increased, even though mortality reductions remained evident.\"}]","Impact of different age ranges on the benefits and harms of the breast cancer screening programme by the EU-TOPIA tool | PDF",1790021503,15,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55dda9f1d07063e43e4e2f5d67c26a4a.webp",983,1269,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b302b34b8aa38a9ffe39b2068ed1cf9.webp",982,1268,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcaa0b3a416df72f1e5c877dace51980.webp",981,1266,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de4c1c6fb6dcfd833f73e0018735f957.webp",980,1265]